

**Biocon Limited**

20th KM, Hosur Road  
Electronic City  
Bangalore 560 100, India  
T 91 80 2808 2808  
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

[www.biocon.com](http://www.biocon.com)

BIO/SECL/TG/2025-26/31

May 15, 2025

To The Manager, <b>BSE Limited</b> Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To The Manager, <b>National Stock Exchange of India Limited</b> Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050
<b>Scrip Code - 532523</b>	<b>Scrip Symbol - BIOCON</b>

**Subject: Notification to Stock Exchanges**

Dear Sir/Madam,

This is to inform you that Biocon Pharma Limited, a wholly owned subsidiary of Biocon Limited, has received approval for its ANDA for Rivaroxaban Tablets USP from the US FDA, for strengths of 2.5 mg, 10 mg, 15 mg and 20 mg. Rivaroxaban is a prescription medication used in the treatment of deep vein thrombosis and pulmonary embolism, to reduce the risk of stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation.

The approval will further strengthen Biocon's portfolio of vertically integrated drug products.

The above information will also be available on the website of the Company at [www.biocon.com](http://www.biocon.com).

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

---

**Siddharth Mittal**  
**Managing Director & CEO**  
**DIN: 03230757**